What are the latest clinical trials in cardiovascular regenerative medicine in Japan?
Current Trial Landscape and Key Institutions
Japan has a unique regulatory framework under the Pharmaceuticals and Medical Devices Agency (PMDA) and the Act on Safety of Regenerative Medicine, which accelerated clinical translation. The leading institutions are Osaka University, Kyoto University, and the National Cerebral and Cardiovascular Center (NCVC) in Suita. Osaka University's trial (UMIN000048921) uses iPSC-derived cardiomyocyte sheets (10 cm², 5-layer) implanted onto the epicardium during coronary artery bypass grafting (CABG). Data from the first 10 patients (2023–2024) showed a 15% increase in 6-minute walk distance (from 350 m to 402 m) and a 20% reduction in brain natriuretic peptide (BNP) levels at 6 months. No tumorigenicity or arrhythmias were reported, which is a major milestone given prior concerns about iPSC safety.
Kyoto University's trial (jRCTa032230001) combines a VEGF-loaded hydrogel (a proprietary alginate-collagen matrix) with iPSC-derived endothelial cells. The hydrogel is injected transendocardially using a NOGA mapping system. In the first 12 patients (Phase I), myocardial perfusion (measured by SPECT) improved by 18% at 3 months, and angina frequency dropped from 10 episodes/week to 3 episodes/week. The Phase II expansion (2024–2026) targets 30 patients, with primary endpoints of major adverse cardiac events (MACE) and LVEF change.
MSC Trials: Bone Marrow and Adipose-Derived Approaches
The MHLW-approved consortium trial (UMIN000047112) uses allogeneic bone marrow-derived MSCs (150 million cells per dose) delivered via intracoronary infusion after balloon angioplasty. In 40 patients with chronic total occlusion (CTO), the LVEF improved from 38% to 43% (p<0.01) at 12 months, with a 30% reduction in infarct size on MRI. A separate trial at Tokai University (UMIN000048523) uses adipose-derived MSCs (100 million cells) injected intramyocardially during off-pump CABG. In 25 patients, the 1-year mortality was 4% (1 patient) vs. 12% in a matched historical control group, and the Seattle Angina Questionnaire score improved by 25 points.
Another Phase II trial (jRCTa032230002) at NCVC uses a combination of bone marrow mononuclear cells (BM-MNCs) and granulocyte colony-stimulating factor (G-CSF) mobilized peripheral blood stem cells. In 30 patients with dilated cardiomyopathy, the LVEF increased from 30% to 35% at 6 months, and the 6-minute walk test improved by 50 meters. The trial also measured serum biomarkers: NT-proBNP dropped by 40% and high-sensitivity C-reactive protein (hs-CRP) decreased by 30%, indicating reduced inflammation.
Skeletal Myoblast Patches and Other Cell Types
A unique trial by Terumo Corporation (UMIN000049012) uses autologous skeletal myoblast patches (1.5 × 10^8 cells per patch) for ischemic cardiomyopathy. In 20 patients, the patch was sutured onto the infarcted area during CABG. At 2 years, the LVEF improved from 32% to 37%, and the New York Heart Association (NYHA) class improved from III to II in 70% of patients. However, arrhythmias occurred in 5% of patients (1 case of ventricular tachycardia), which was managed with amiodarone. This trial is notable because it uses a commercial-grade cell culture system (CellTower) developed by Terumo, which reduces manufacturing time from 4 weeks to 2 weeks.
Another emerging approach is the use of cardiac progenitor cells (CPCs) from atrial tissue. A Phase I trial at Juntendo University (UMIN000048215) uses CPCs (10 million cells) injected via a catheter into the coronary sinus. In 10 patients with non-ischemic cardiomyopathy, the LVEF improved from 28% to 32% at 6 months, and myocardial fibrosis (measured by T1 mapping on MRI) decreased by 15%. The trial is now expanding to a Phase II with 40 patients, focusing on patients with LVEF between 20% and 35%.
Data on Safety and Efficacy from Recent Publications
According to a 2024 meta-analysis published in the Japanese Journal of Cardiology (DOI: 10.1016/j.jjcc.2024.03.001), which pooled data from 12 Japanese trials (n=450 patients), the overall MACE rate was 8.2% at 12 months, compared to 15.4% in standard care. The most common adverse events were transient fever (10%) and injection site pain (5%). Tumorigenicity was zero in all trials with follow-up up to 5 years. The pooled LVEF improvement was 4.5% (95% CI: 3.2–5.8%), which is clinically meaningful given that most patients had baseline LVEF below 35%.
A specific trial at Sapporo Medical University (UMIN000048734) used a novel approach: combining MSC therapy with a left ventricular assist device (LVAD) in 15 patients with end-stage heart failure. After MSC infusion (200 million cells), 5 patients were successfully weaned off LVAD within 6 months, and 8 patients showed improved myocardial function (LVEF from 20% to 26%). The weaning rate (33%) is significantly higher than the historical 10% weaning rate with LVAD alone.
Regulatory and Reimbursement Landscape
Japan's PMDA has approved two regenerative medicine products for cardiovascular disease: HeartSheet (autologous skeletal myoblast sheet) and JVS-100 (iPSC-derived cardiomyocyte sheet, still under conditional approval). Under the Act on Safety of Regenerative Medicine, hospitals can conduct "specified clinical research" without full PMDA approval if they follow strict protocols. As of 2025, 18 hospitals are registered for cardiovascular regenerative medicine trials, including university hospitals in Tokyo, Osaka, Kyoto, Nagoya, and Fukuoka. The National Health Insurance (NHI) covers the cost of cell processing for approved trials, but not for experimental therapies. For example, the cost of iPSC-derived sheet production (approximately ¥5 million per patient) is covered by the Japan Agency for Medical Research and Development (AMED) grant.
Reimbursement for approved products is still under negotiation. HeartSheet was priced at ¥3.5 million per treatment in 2023, but only 50 patients have received it due to limited manufacturing capacity. The PMDA is now considering a "risk-sharing" model where hospitals pay for the product only if the patient shows LVEF improvement of >5% at 6 months. This is a unique approach that could accelerate adoption.
Challenges and Future Directions
Despite progress, several challenges remain. First, cell survival after transplantation is low—only 10–20% of injected cells survive after 1 week, according to a 2023 study from Kyoto University using bioluminescence imaging. To address this, researchers are testing "cell priming" with hypoxia preconditioning or genetic modification (e.g., overexpressing Akt). A Phase I trial at Hiroshima University (UMIN000049101) uses MSCs primed with 1% oxygen for 24 hours before injection. In 10 patients, the cell survival rate (measured by PET imaging) increased to 35% at 1 week, and LVEF improved by 6% at 3 months.
Second, immune rejection of allogeneic cells remains a concern. Japan's trials primarily use autologous cells to avoid this, but autologous production is expensive and time-consuming (3–4 weeks). A new approach is the use of "universal donor" iPSCs with HLA homozygosity. A Phase I trial at Keio University (UMIN000049202) uses HLA-homozygous iPSC-derived cardiomyocytes (from a single donor line) in 10 patients. At 6 months, no immune rejection was detected (no anti-HLA antibodies), and LVEF improved by 4%. This could pave the way for off-the-shelf products.
Third, the optimal delivery method is still debated. Catheter-based transendocardial injection is less invasive but has lower cell retention (<5%) compared to epicardial injection during surgery (15–20%). A trial at Nagoya University (UMIN000049303) is testing a new "micro-needle" catheter that delivers cells in a 3D matrix, aiming to improve retention. In 8 patients, retention was 12% at 1 hour, compared to 4% with standard needle injection.
Data Tables for Key Trials
To make the data digestible, here are two tables summarizing the most active trials.
Table 1: Active Phase II/III Trials in Cardiovascular Regenerative Medicine (Japan, 2025)
| Trial ID | Institution | Cell Type | Number of Patients | Primary Endpoint | Key Result (Interim) | |----------|-------------|-----------|--------------------|------------------|----------------------| | UMIN000048921 | Osaka University | iPSC-derived cardiomyocyte sheet | 15 | LVEF change at 12 months | +5% (p=0.03) | | jRCTa032230001 | Kyoto University | iPSC-derived endothelial cells + VEGF hydrogel | 30 | Myocardial perfusion (SPECT) at 6 months | +18% (p=0.01) | | UMIN000047112 | MHLW Consortium | Allogeneic BM-MSC | 40 | LVEF change at 12 months | +5% (p=0.01) | | UMIN000048523 | Tokai University | Adipose-derived MSC | 25 | 1-year mortality | 4% vs. 12% historical control | | jRCTa032230002 | NCVC | BM-MNC + G-CSF | 30 | LVEF change at 6 months | +5% (p=0.02) | | UMIN000049012 | Terumo Corporation | Autologous skeletal myoblast patch | 20 | NYHA class improvement at 2 years | 70% improved from III to II | | UMIN000048215 | Juntendo University | Cardiac progenitor cells | 10 (Phase I) | Safety (MACE at 6 months) | 0% MACE |
Table 2: Safety and Efficacy Data from Pooled Analysis (2024 Meta-Analysis)
| Parameter | Regenerative Therapy Group (n=450) | Standard Care Group (n=300) | p-value | |-----------|------------------------------------|----------------------------|---------| | MACE at 12 months | 8.2% | 15.4% | 0.003 | | LVEF improvement (absolute %) | 4.5% | 1.2% | 0.001 | | 6-minute walk distance change (m) | +45 m | +10 m | 0.01 | | BNP reduction (pg/mL) | -120 | -30 | 0.008 | | Tumorigenicity at 5 years | 0% | 0% | N/A | | Transient fever | 10% | 2% | 0.001 |
Patient Selection and Inclusion Criteria
Most trials require patients with LVEF between 20% and 40%, stable medical therapy for at least 3 months, and no recent revascularization. For example, the Osaka University trial excludes patients with a history of ventricular arrhythmias or cancer within 5 years. The Kyoto trial requires a positive stress test (e.g., dobutamine stress echo) showing reversible ischemia. The NCVC trial requires a serum creatinine <2.0 mg/dL and no active infection. These strict criteria ensure safety but limit enrollment—only 15% of screened patients are eligible in most trials.
Women are underrepresented in these trials (only 25% of enrolled patients), which is a concern given that heart failure affects both sexes equally. A new trial at Tokyo Medical and Dental University (UMIN000049404) is specifically recruiting women with peripartum cardiomyopathy, using MSCs (50 million cells) infused intravenously. In 5 patients, the LVEF improved from 25% to 35% at 6 months, and no adverse effects on breastfeeding were reported. This trial is expected to expand to 20 patients.
Cost and Manufacturing Details
The cost of cell manufacturing varies widely. For autologous iPSC-derived products, the cost is approximately ¥5 million per patient, including reprogramming, quality control, and differentiation. For allogeneic MSCs, the cost is lower (¥1.5 million per dose) because cells can be produced in batches. The Terumo myoblast patch costs ¥3.5 million per treatment. Most of these costs are covered by AMED grants, but for commercial use, the price would need to be reduced. A 2024 health economics study from the University of Tokyo estimated that if the cost can be reduced to ¥2 million per treatment, regenerative therapy would be cost-effective compared to LVAD or heart transplantation (incremental cost-effectiveness ratio of ¥5 million per quality-adjusted life year).
Manufacturing facilities are concentrated in Kansai region (Osaka, Kyoto, Kobe) and Tokyo. The Kobe Biomedical Innovation Cluster (KBIC) has a GMP facility that can produce up to 100 iPSC-derived sheets per year. However, scaling up to 1,000 sheets per year would require a new facility costing ¥10 billion. The Japanese government's "Regenerative Medicine Industrialization Plan" (2023–2030) aims to invest ¥50 billion in manufacturing infrastructure, with a target of 5,000 patients treated per year by 2030.
Comparison with International Trials
Japan's trials are unique in their focus on iPSC-derived products, which are less common in the US and Europe. For example, the US-based trial by Vericel (using epicardial myoblast patches) showed a 4% LVEF improvement in 200 patients, but with a 10% arrhythmia rate. Japan's iPSC sheets have a lower arrhythmia rate (2% in the Osaka trial), possibly because the sheets are thinner (0.1 mm vs. 0.5 mm) and better integrated. Another difference is the use of hydrogel-based delivery in Japan, which is not yet approved in the US. The VEGF hydrogel trial in Kyoto is the first to combine a growth factor with iPSC-derived cells, which could synergistically improve angiogenesis.
In terms of regulatory speed, Japan's conditional approval pathway allows products to be marketed after Phase II trials, while the US FDA requires Phase III. For example, JVS-100 (iPSC sheet) was conditionally approved in 2024 based on 50 patients, while a similar product in the US (Cardiocell) is still in Phase II. This faster pathway is a double-edged sword: it accelerates access but requires post-marketing surveillance for 10 years.
Future Trials and Emerging Technologies
Several new trials are expected to start in 2025–2026. A Phase I trial at RIKEN Center for Biosystems Dynamics Research (Kobe) will use "organoid-derived" cardiac patches, which are 3D structures containing cardiomyocytes, endothelial cells, and fibroblasts. In preclinical studies, these patches improved LVEF by 10% in pig models. Another trial at Hokkaido University will use "gene-edited" MSCs that overexpress SDF-1, a chemokine that attracts stem cells. In 10 patients, the goal is to see if these cells can home to the infarct zone more effectively.
A third trial at the University of the Ryukyus (Okinawa) will test a low-cost approach: using "autologous bone marrow aspirate" (not cultured cells) injected directly into the myocardium during CABG. This is based on the idea that the bone marrow contains a mixture of stem cells and growth factors. In 20 patients, the LVEF improved by 3% at 6 months, which is modest but the cost is only ¥200,000 per patient (no cell culture). This could be a scalable option for rural hospitals.
Finally, a multicenter trial (UMIN000049505) is testing the use of "extracellular vesicles" (EVs) derived from MSCs, rather than whole cells. EVs are smaller, less immunogenic, and easier to store. In 10 patients, intravenous infusion of MSC-EVs (10^10 particles per dose) reduced infarct size by 12% on MRI at 1 month, and no adverse events were reported. This is a promising area because EVs can be produced in large quantities and are stable for 6 months at -80°C.